Neoadjuvant Endocrine Therapy in Breast Cancer

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and post-menopausal group with highly endocrine responsive operable mammary carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong General Hospital; Guangdong Provincial People's Hospital
• Treatments: Letrozole

Criteria

Inclusion Criteria:

1. Females ≥18 years

2. ER-positive (≥50%), PgR-positive (≥50% ), HER2-negative, and previously untreated, non-metastatic primary invasive BC.

3. The tumour size had to be >1 cm.

Exclusion Criteria:

1. male patients;

2. patients with inflammatory breast cancer or distant metastasis;

3. patients who were previously treatment treated with chemotherapy, radiation therapy or prior treatment with AIs or antiestrogens for breast cancer;

4. patients with a second concomitant neoplasm;

5. patients who could not meet the eligibility criteria.